Optimizing the treatment of NLPHL for every patient.

The Global nLPHL One Working Group (GLOW) is a multidisciplinary group that facilitates national and international research partnerships to optimize the diagnosis, care, and outcomes for (and with) patients diagnosed with NLPHL worldwide.

We serve as a coordinated hub for NLPHL research across the age continuum.

What's new from GLOW?

We held our 4th GLOW Summit in Cologne, Germany in October 2026. You can watch the recording here.

Our patient decision aid for patients with completely removed (stage IA) NLPHL is complete as of September 2026! View the decision aid and evidence review tables documents here.

FAST FACTS ABOUT GLOW

2020

GLOW started in 2020 with the aim of uniting pediatric and adult lymphoma researchers to study NLPHL and optimize care across the age continuum.

>200 researchers

GLOW researchers represent pediatric and adult oncology, radiation oncology, pathology, biostatistics, pyschology, and survivorship.

>35 countries

GLOW researchers and patient advocates come from all over the world to improve outcomes for patients.

>70 patient advocates

GLOW patient advocates include patients, care partners, and staff from cancer support organizations who collaborate on GLOW projects and help disseminate GLOW findings.

8 publications

GLOW research has been published in academic journals including the Journal of Clinical Oncology, Blood, and Leukemia.

6 research committees

GLOW has diverse research committees that study various ways of improving patient outcomes, from large scale retrospective survival outcomes analyses to patient decision aids.

>25 posters & presentations

GLOW researchers are active at national and international academic meetings, where we share our research findings and generate new research questions.

1 clinical trial in progress

In 2026, GLOW received funds to launch our first prospective clinical trial to study de-intensified treatments for patients with low-risk disease.

WHAT MAKES US DIFFERENT?

We are learning from past research and experience, so we:

  • Created the first global network of pediatric, adolescent, and adult Hodgkin lymphoma experts to study NLPHL together.
  • Recruited experts in consortium governance and consortium management to facilitate international, multi-specialty collaboration, streamline administrative tasks to maximize time and resources, and coordinate core research activities.
  • Partner with patient and caregiver advocates to inform research priorities, educational opportunities, and community engagement.
  • Maintain a database of over 2,000 cases of NLPHL representing all age groups and all stages worldwide to discover risk and predictive factors.
  • Created a centralized tissue bank for NLPHL pathology and translational biology research.
  • Collaborate with NODAL and Data for the Common Good to incorporate data standards and streamline international data sharing workflows.